Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: XPhyto Therapeutics Corp. XPHYF

MissionIRNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Receives European Approval for 25 Minute COVID-19 PCR Test

Posted on March 18, 2021 by MissionIR

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT),a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, along with its German diagnostics development partner, 3a-diagnostics GmbH (“3a”), has received European approval of its point-of-care SARS-CoV-2 RT-PCR … Continue reading →

Posted in MissionIRNewsBreaks, XPhyto Therapeutics Corp. XPHYF | Leave a comment

MissionIRNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Featured in Latest Episode of Bell2Bell Podcast

Posted on March 12, 2021 by MissionIR

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) was featured in the The Bell2Bell Podcast, a part of InvestorBrandNetwork’s (“IBN”) sustained effort to provide specialized content distribution via widespread syndication channels. XPhyto Therapeutics’ CEO and Director, Hugh Rogers, joined the … Continue reading →

Posted in MissionIRNewsBreaks, XPhyto Therapeutics Corp. XPHYF | Leave a comment

MissionIRNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announced Partner Has Received ISO Certification for Rapid COVID-19 Test

Posted on March 10, 2021 by MissionIR

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, has announced that 3a-diagnostics GmbH (“3a”) has received EN ISO 13485 certification for its rapid point-of-care, SARS-CoV-2 RT-PCR … Continue reading →

Posted in XPhyto Therapeutics Corp. XPHYF | Leave a comment

MissionIRNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Unveils New Website, Completion of Corporate Rebranding Strategy

Posted on March 4, 2021 by MissionIR

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, announced that it has completed its corporate rebranding efforts. Those efforts included the launch of a completely redesigned … Continue reading →

Posted in MissionIRNewsBreaks, XPhyto Therapeutics Corp. XPHYF | Leave a comment

MissionIRNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Releases Update on Promotional and Marketing Activity Comments

Posted on March 1, 2021 by MissionIR

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, has provided an update to its Jan. 22, 2021, press release regarding recent promotional and investor relations. The … Continue reading →

Posted in XPhyto Therapeutics Corp. XPHYF | Leave a comment

MissionIRNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces First Order for Rapid COVID-19 Test

Posted on February 24, 2021 by MissionIR

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, has placed an initial order for rapid point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system. The test systems, known as … Continue reading →

Posted in MissionIRNewsBreaks, XPhyto Therapeutics Corp. XPHYF | Leave a comment

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Advances Rapid COVID Test System, Expands Psychedelic Medicine Programs

Posted on February 22, 2021 by MissionIR

Life sciences industry accelerator XPhyto Therapeutics Corp. has developed a timeline for the approval and rollout of a rapid, portable COVID-19 test it expects to become available by April in Europe XPhyto’s Covid-ID Lab system is designed to help industries … Continue reading →

Posted in XPhyto Therapeutics Corp. XPHYF | Leave a comment

MissionIRNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Expedited Formation of Team to Launch Test System, Also Comments on Lawsuit Against German Subsidiary

Posted on February 22, 2021 by MissionIR

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) announced that it has accelerated the creation of a commercial team formed to launch its point-of-care COVID-19 RT-PCR (“RT-PCR”) test system, called the COVID ID Lab. The lab was developed by XPhyto’s exclusive … Continue reading →

Posted in XPhyto Therapeutics Corp. XPHYF | Leave a comment

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Outlines 2021 Business Strategies for COVID-19 PCR Testing and Psychedelic Treatments

Posted on February 16, 2021 by MissionIR

XPhyto Therapeutics Corp. plans to commercialize its rapid and portable PCR Kit this year to provide point-of-care diagnostics The company is confident about the successful validation of the PCR kit for the European commercial (CE-IVD) approval in Q1 2021 Hugh … Continue reading →

Posted in XPhyto Therapeutics Corp. XPHYF | Leave a comment

MissionIRNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Completion of European CE-IVD Application for 25-Minute COVID-19 RT-PCR Test

Posted on February 16, 2021 by MissionIR

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) has made a significant announcement, along with its exclusive German diagnostics development partner, 3a-diagnostics GmbH (“3a”). The companies have completed all actions and procedures required for the European regulatory application for the rapid … Continue reading →

Posted in XPhyto Therapeutics Corp. XPHYF | Leave a comment